Volume 15, Issue 4 (September 2023 2023)                   Iranian Journal of Blood and Cancer 2023, 15(4): 293-303 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

E. Khamseh M, Malek M, Hashemi-madani N, Ghassemi F, Rahimian N, Ziaee A, et al . Guideline for the diagnosis and treatment of diabetes mellitus in patients with transfusion-dependent thalassemia. Iranian Journal of Blood and Cancer 2023; 15 (4) :293-303
URL: http://ijbc.ir/article-1-1424-en.html
1- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran.
2- Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran.
3- Pediatric Growth and Development Research Center, Iran University of medical sciences, Tehran-Iran
4- Pediatric Growth and Development Research Center, Iran University of medical sciences, Tehran-Iran , faranoush47@gmail.com
Abstract:   (556 Views)

Thalassemia major hemoglobinopathy requires regular blood transfusions, often leading to iron overload due to repeated transfusions and increased intestinal iron absorption. The association between thalassemia major and metabolic complications, including diabetes and metabolic syndrome, has been recognized due to iron overload, insulin secretion impairment, insulin resistance, hepatic dysfunction, and other endocrine complications. These hormonal imbalances can also influence glucose metabolism and contribute to the development of metabolic syndrome. It's essential for individuals with thalassemia major to undergo regular monitoring of their glucose metabolism, including periodic assessments of fasting blood glucose, oral glucose tolerance tests, and measurement of Fructosamine. Early detection and management of diabetes and metabolic syndrome in thalassemia major patients are crucial to minimize complications and optimize overall health. Medical management may involve a combination of regular blood transfusions, iron chelation therapy to reduce iron overload, lifestyle modifications such as a healthy diet and physical activity, and, if needed, pharmacological interventions for glycemic control. Close collaboration between hematologists and endocrinologists is often necessary to provide comprehensive care for individuals with thalassemia major and metabolic complications. 

Full-Text [PDF 3661 kb]   (349 Downloads)    
: Original Article | Subject: Adults Hematology & Oncology
Received: 2023/07/26 | Accepted: 2023/09/21 | Published: 2023/09/27

References
1. Ehsanipour F, Faranoush P, Foroughi-Gilvaee MR, Sadighnia N, Fallahpour M, Motamedi M, et al. Evaluation of immune system in patients with transfusion-dependent beta-thalassemia in Rasoul-e-Akram Hospital in 2021: A descriptive cross-sectional study. Health Science Reports. 2022;5(6):e871. [DOI:10.1002/hsr2.871]
2. Faranoush P, Jahandideh A, Nekouian R, Mortazavi P. Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research. Veterinary Medicine and Science. 2023;9(3):1426-37. [DOI:10.1002/vms3.1109]
3. Hashemi-madani N, Rahimian N, Khamseh ME, Faranoush P, Malek M, Ghasemi F, et al. Guideline for the diagnosis and treatment of hypothyroidism and hypoparathyroidism in patients with blood transfusion-dependent thalassemia. Iranian Journal of Blood and Cancer. 2023;15(2):89-96. [DOI:10.58209/ijbc.15.2.89]
4. Jaruratanasirikul S, Chareonmuang R, Wongcharnchailert M, Laosombat V, Sangsupavanich P, Leetanaporn K. Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy. Eur J Pediatr. 2008;167(8):873-6. [DOI:10.1007/s00431-007-0602-0]
5. Kattamis C, Ladis V, Tsoussis D, Kaloumenou I, Theodoridis C. Evolution of glucose intolerance and diabetes in transfused patients with thalassemia. Pediatr Endocrinol Rev. 2004;2 Suppl 2:267-71.
6. Azami M, Sayehmiri K. Prevalence of Diabetes Mellitus in Iranian Patients with Thalassemia Major: A Systematic Review and Meta-Analysis. Journal of Mazandaran University of Medical Sciences. 2016;26(141):192-204.
7. Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa MR. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev. 2004;2 Suppl 2:285-91.
8. Martirosyan D, Jahanbakhshi F, Foroughi-Gilvaee MR, Mousavi F, Faranoush P, Ashoori MR, et al. Evaluation of the effect of electron beam therapy on oxidative stress and some minerals in patients with type 2 diabetes mellitus. Functional Food Science. 2022;2(5):124-35. [DOI:10.31989/ffs.v2i5.935]
9. Olivatto GM, Teixeira CRS, Sisdelli MG, Zanetti ML, Silveira R, Gonçalves CV. Characterization of thalassemia major and diabetes mellitus patients at a reference center in Brazil. Hematol Transfus Cell Ther. 2019;41(2):139-44. [DOI:10.1016/j.htct.2018.08.005]
10. Mobarra N, Shanaki M, Ehteram H, Nasiri H, Sahmani M, Saeidi M, et al. A Review on Iron Chelators in Treatment of Iron Overload Syndromes. Int J Hematol Oncol Stem Cell Res. 2016;10(4):239-47.
11. De Sanctis V, Soliman AT, Canatan D, Tzoulis P, Daar S, Di Maio S, et al. An ICET-A survey on occult and emerging endocrine complications in patients with β-thalassemia major: Conclusions and recommendations. Acta Biomed. 2019;89(4):481-9.
12. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76-131. [DOI:10.1210/er.2006-0043]
13. Faranoush M, Faranoush P, Heydari I, Foroughi-Gilvaee MR, Azarkeivan A, Parsai Kia A, et al. Complications in patients with transfusion dependent thalassemia: A descriptive cross-sectional study. Health Science Reports. 2023;6(10):e1624. [DOI:10.1002/hsr2.1624]
14. Tzoulis P, Shah F, Jones R, Prescott E, Barnard M. Joint diabetes thalassaemia clinic: an effective new model of care. Hemoglobin. 2014;38(2):104-10. [DOI:10.3109/03630269.2013.862541]
15. Farmakis D, Porter J, Taher A, Domenica Cappellini M, Angastiniotis M, Eleftheriou A. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere. 2022;6(8):e732. [DOI:10.1097/HS9.0000000000000732]
16. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab. 1993;77(2):478-83. https://doi.org/10.1210/jcem.77.2.8345055 [DOI:10.1210/jc.77.2.478]
17. Nouri-Vaskeh M, Khalili N, Khalaji A, Behnam P, Alizadeh L, Ebrahimi S, et al. Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. Archives of Physiology and Biochemistry. 2023;129(2):373-8. [DOI:10.1080/13813455.2020.1828479]
18. Bayanzay K, Alzoebie L. Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. J Blood Med. 2016;7:159-69. https://doi.org/10.2147/JBM.S61540 [DOI:10.2147/JBM.S120071]
19. Faranoush P, Elahinia A, Ziaee A, Faranoush M. Review of endocrine complications in transfusion-dependent thalassemia. Iranian Journal of Blood and Cancer. 2023;15(4):212-35.
20. Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes. 2015;6(2):296-303. [DOI:10.4239/wjd.v6.i2.296]
21. Stuebe AM, Mantzoros C, Kleinman K, Gillman MW, Rifas-Shiman S, Seely E, et al. Gestational glucose tolerance and maternal metabolic profile at 3 years postpartum. Obstetrics and gynecology. 2011;118(5):1065. [DOI:10.1097/AOG.0b013e3182325f5a]
22. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1(Suppl 1):S62-7. [DOI:10.2337/dc09-S062]
23. Ghosh S, Collier A. Section 1 - Diagnosis, classification, epidemiology and biochemistry. In: Ghosh S, Collier A, editors. Churchill's Pocketbook of Diabetes (Second Edition) (Second Edition). Oxford: Churchill Livingstone; 2012. p. 1-49. [DOI:10.1016/B978-0-443-10081-9.00008-7]
24. Wile DB, Wilding JPH. CHAPTER 15 - Glucose metabolism and the pathophysiology of diabetes mellitus. In: Marshall WJ, Lapsley M, Day AP, Ayling RM, editors. Clinical Biochemistry: Metabolic and Clinical Aspects (Third Edition): Churchill Livingstone; 2014. p. 273-304. [DOI:10.1016/B978-0-7020-5140-1.00015-8]
25. Association AD. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2019;43(Supplement_1):S14-S31. [DOI:10.2337/dc20-S002]
26. Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Prediabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55(9). [DOI:10.3390/medicina55090546]
27. Danese E, Montagnana M, Nouvenne A, Lippi G. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol. 2015;9(2):169-76. [DOI:10.1177/1932296814567227]
28. Zhang X, Xiao Y, Fan Y. Investigating the Reliability of HbA1c Monitoring for Blood Glucose Control During Late Pregnancy in Patients with Gestational Diabetes Mellitus (GDM) with and without β-Thalassemia Minor. Diabetes Ther. 2018;9(6):2305-13. [DOI:10.1007/s13300-018-0516-z]
29. De Sanctis V, Soliman A, Tzoulis P, Daar S, Kattamis A, Delaporta P, et al. The The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network. Acta Biomed. 2022;93(2):e2022162.
30. Hur KY, Kim MK, Ko SH, Han M, Lee DW, Kwon HS. Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement. Diabetes Metab J. 2020;44(1):3-10. [DOI:10.4093/dmj.2020.0004]
31. Heaf J. Metformin in chronic kidney disease: time for a rethink. Perit Dial Int. 2014;34(4):353-7. [DOI:10.3747/pdi.2013.00344]
32. Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind. World J Diabetes. 2021;12(7):916-31. [DOI:10.4239/wjd.v12.i7.916]
33. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754-61. [DOI:10.1210/jc.2015-3754]
34. Al-Faris EA. Guidelines for the management of diabetic patients in the health centers of saudi arabia. J Family Community Med. 1997;4(1):12-23. [DOI:10.4103/2230-8229.98445]
35. Saliba AN, Atoui A, Labban M, Hamade H, Bou-Fakhredin R, Mufarrij A, et al. Thalassemia in the emergency department: special considerations for a rare disease. Ann Hematol. 2020;99(9):1967-77. [DOI:10.1007/s00277-020-04164-6]
36. Barnard M, Tzoulis P. Diabetes and thalassaemia. Thalassemia Reports. 2013;3(s1):e18. [DOI:10.4081/thal.2013.s1.e18]
37. Haghpanah S, Davani M, Samadi B, Ashrafi A, Karimi M. Serum lipid profiles in patients with beta-thalassemia major and intermedia in southern Iran. J Res Med Sci. 2010;15(3):150-4.
38. Bazi A, Sharifi-Rad J, Rostami D, Sargazi-Aval O, Safa A. Diabetes Mellitus in Thalassaemia Major Patients: A Report from the Southeast of Iran. J Clin Diagn Res. 2017;11(5):Bc01-bc4. [DOI:10.7860/JCDR/2017/24762.9806]
39. Wysocka-Mincewicz M, Gołębiewska J, Olechowski A, Szalecki M. Diabetic Retinopathy in Children with Type 1 Diabetes-Occurrence and Screening Using Optical Coherence Tomography. Life (Basel). 2021;11(6). [DOI:10.3390/life11060590]
40. Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412-8. [DOI:10.2337/dc16-2641]
41. Mallika P, Tan A, S A, T A, Alwi SS, Intan G. Diabetic retinopathy and the effect of pregnancy. Malays Fam Physician. 2010;5(1):2-5.
42. Alleyn CR, Volkening LK, Wolfson J, Rodriguez-Ventura A, Wood JR, Laffel LM. Occurrence of microalbuminuria in young people with Type 1 diabetes: importance of age and diabetes duration. Diabet Med. 2010;27(5):532-7. [DOI:10.1111/j.1464-5491.2010.02983.x]
43. Muntean C, Starcea IM, Banescu C. Diabetic kidney disease in pediatric patients: A current review. World Journal of Diabetes. 2022;13(8):587. [DOI:10.4239/wjd.v13.i8.587]
44. Weckmann GF, Stracke S, Haase A, Spallek J, Ludwig F, Angelow A, et al. Diagnosis and management of non-dialysis chronic kidney disease in ambulatory care: a systematic review of clinical practice guidelines. BMC nephrology. 2018;19(1):1-18. [DOI:10.1186/s12882-018-1048-5]
45. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S175-s84. [DOI:10.2337/dc22-S011]
46. Risk Factors for Diabetic Peripheral Neuropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study. Diabetes Care. 2021;45(5):1065-72. [DOI:10.2337/dc21-1074]
47. Herman W, Pop‐Busui R, Braffett B, Martin C, Cleary P, Albers J, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabetic medicine. 2012;29(7):937-44. [DOI:10.1111/j.1464-5491.2012.03644.x]
48. Kumar S, Fernando D, Veves A, Knowles E, Young M, Boulton A. Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes research and clinical practice. 1991;13(1-2):63-7. [DOI:10.1016/0168-8227(91)90034-B]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb